BlinkLab (ASX:BB1) recruited 54 out of 100 children for the initial phase of its US autism diagnostic clinical trial, according to a Tuesday filing with the Australian bourse.
The study aims to validate the BlinkLab Dx1 neurological test as a diagnostic aid for clinicians in early assessment of developmental disorders, the filing said.
The company is expected to complete enrolment and data analysis of the initial study by the third quarter of the year, per the filing.
Shares fell past 1% in afternoon trade Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。